Asia
Anima Biotech’s strategic collaboration with Takeda Pharmaceutical, just announced today, uses its novel platform for discovery of mRNA translation modulators to discover and develop a new class of therapies for neurological diseases.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
With more European countries pausing dosing of AstraZeneca’s COVID-19 vaccine over concerns about potential blood clotting side effects, Russia is seeking to fill in the gaps with its Sputnik V vaccine.
Nearly five years to the day after striking the deal, AVEO Oncology and CANbridge Life Sciences announce the termination of their collaboration and licensing agreement for AVEO’s AV-203.
The Japanese pharma giant is aiming for double-digit revenue growth of its Growth and Emerging Markets Business Unit (GEM BU) by 2030. Here’s how they plan to do it.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
Days after vaccine-maker Bharat Biotech released interim Phase III efficacy data for a COVID-19 vaccine already in use in India, a pulmonary expert is expressing enthusiasm for the company’s next-generation intranasal vaccine on track to enter clinical testing this quarter.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Takeda will develop soticlestat, a first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), as a potential treatment for developmental and epileptic encephalopathies.
PRESS RELEASES